Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 10/20 | 0.32 |
| ▸ | ACHE | P22303 | 10/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5894390 | 0.70 | ATM (0.43) | ATMBCHEACHE | |
| SCHEMBL28205936 | 0.65 | ATM (0.48) | ATMMEN1KMT2ANPC1BCHE | |
| SCHEMBL253244 | 0.64 | ATM (0.41) | ATMNPC1BCHEACHERAB9A | |
| SCHEMBL3084819 | 0.64 | ATM (1.00) | ATMMEN1KMT2ANPC1BCHE | |
| SCHEMBL9447797 | 0.63 | CYP1A2 (0.41) | NPC1 | |
| SCHEMBL21694450 | 0.62 | ATM (0.48) | ATMMEN1KMT2ANPC1RAB9A | |
| SCHEMBL7501877 | 0.60 | ATM (0.69) | ATMMEN1KMT2ANPC1ACHE | |
| SCHEMBL51581 | 0.60 | ATM (0.41) | ATMNPC1RAB9A | |
| SCHEMBL379226 | 0.59 | ATM (0.36) | ATMMEN1KMT2A | |
| SCHEMBL7869230 | 0.59 | ATM (0.40) | ATMNPC1BCHEACHERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6432944-B1 | ARYLACETAMIDOALANYL DERIVATIVES OF BENZODIAZEPINONES ARE USEFUL FOR INHIBITION OF EXTRACELLULAR DEPOSITION OF BETA-AMYLOID PEPTIDE, THUS TREATS AMYLOIDOSIS, ALZHEIMER'S DISEASE AND DOWN'S SYNDROME | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-13 | — | — | US | disclosed |
| US-20020022621-A1 | Benzodiazepinone beta -amyloid inhibitors: arylacetamidoalanyl derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-21 | — | — | US | disclosed |
| US-5817751-A | IMMOBILIZATION AN AMINOACID ON SUPPORT; CYCLIZATION | AFFYMAX TECHNOLOGIES N.V. (GB) | 1998-10-06 | — | — | US | disclosed |
| WO-1996000391-A1 | METHODS FOR THE SYNTHESIS OF DIKETOPIPERAZINES | AFFYMAX TECHNOLOGIES N.V. (AN) | 1996-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022621-A1 | Benzodiazepinone beta -amyloid inhibitors: arylacetamidoalanyl derivatives | APP, BACE1, PSEN1 | ATM 3298/4885MEN1 4031/4885KMT2A 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.